Status:

RECRUITING

Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Ministry of Health, France

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

40-90 years

Phase:

PHASE3

Brief Summary

Knee OsteoArthritis (KOA) is a common disease associated with pain and impaired function. Many patients are not relieved of their symptoms with enough efficacy by conservative treatments. Genicular Ar...

Detailed Description

Patients will be screened during current practice consultation in each recruiting center (Screening Visit). When a patient will meet the eligibility criteria, he will be informed about the protocol. ...

Eligibility Criteria

Inclusion

  • Diagnosis of primary KOA according to the classification of the American College of Rheumatology (ACR) (5)
  • Radiographic Kellgren and Lawrence score ≥ 2 (6)
  • VAS pain score ≥ 40 mm (scale 0-100 mm)
  • Previous intra-articular injection in the target knee
  • Patient not eligible to knee surgery
  • For woman of childbearing potential: negative bêta-HCG before randomization
  • Social security affiliation
  • Signed informed consent
  • Good understanding of the French language

Exclusion

  • Intra-articular injection of any product in the target joint within 3 months before embolization
  • Prior knee surgery other than ligament repair
  • Any inflammatory joint disease other than osteoarthritis
  • Any contra-indication to puncture of the ipsilateral femoral artery
  • Current treatment with cyclosporine, tacrolimus, cisplatine, vancomycine, amphotericine B or any aminoside
  • Ipsilateral symptomatic hip OA
  • Treated hyperthyroidism
  • Known severe allergy to Lipiodol® and/or iodine contrast medium
  • Known moderate to severe kidney failure (creatinine clearance \< 30 45 ml/min)
  • Known right-to-left cardiac shunt or intra-tumoral vascular shunt
  • Asthma attack in the 8 days before randomization
  • Exploration or treatment with radioactive iodine scheduled within 1 month after randomization
  • Symptomatic atheromatous lesion in the ipsilateral limb
  • Patient unable or unwilling to comply with the follow-up schedule (at the investigator's discretion)
  • Vulnerable populations (such as pregnant or breastfeeding women, patient under guardianship curatorship, deprived of liberty)
  • Patient under exclusion period in another trial
  • Patient on AME (state medical aid)

Key Trial Info

Start Date :

September 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2028

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT06497140

Start Date

September 30 2024

End Date

October 1 2028

Last Update

October 15 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Hôpital Saint Antoine - APHP

Paris, France, 75012

2

Hôpital Cochin - APHP

Paris, France, 75014

3

Hôpital européen Georges Pomidou - APHP

Paris, France, 75015